[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K: A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res; 2003 Oct 15;9(13):4756-60
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
  • PURPOSE: The aim of this study was to examine the effect of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients.
  • EXPERIMENTAL DESIGN: This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in the rectum.
  • We reviewed the videotapes to measure the number and size of polyps in the same area throughout the study period in each individual patient.
  • RESULTS: The polyp number, measured as the percentage of change from the baseline values, was significantly decreased in the rofecoxib group at 3, 6, and 9 months.
  • At 9 months, the polyp number in the rofecoxib group decreased by 6.8% from the baseline values, whereas that in the placebo group increased by 3.1%.
  • At 9 months, the rofecoxib group showed a significant reduction from the baseline in polyp size as compared with the placebo group (-16.2% versus 1.5%; P < 0.001).
  • There was no statistically significant increase in the incidence of any adverse events in treatment with rofecoxib compared with placebo (P = 0.922).
  • CONCLUSIONS: In this study, once-daily treatment with 25 mg rofecoxib, a cyclooxygenase 2-specific inhibitor, significantly decreased the number and size of rectal polyps in familial adenomatous polyposis patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Colonic Polyps / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors. Lactones / therapeutic use
  • [MeSH-minor] Adult. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Progression. Double-Blind Method. Endoscopy. Female. Humans. Male. Membrane Proteins. Microscopy, Video. Middle Aged. Placebos. Prostaglandin-Endoperoxide Synthases. Sulfones. Time Factors

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14581346.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Lactones; 0 / Membrane Proteins; 0 / Placebos; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


2. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res; 2000 Sep 15;60(18):5151-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.
  • Our experiments demonstrate that mRNA transcripts for guanylin and uroguanylin are markedly reduced in colon polyps and adenocarcinomas.
  • In contrast, a specific uroguanylin-R-GC, R-GCC, is expressed in polyps and adenocarcinomas at levels comparable with normal colon mucosa.
  • Therefore, down-regulation of gene expression and loss of the peptides may interfere with renewal and/or removal of the epithelial cells resulting in the formation of polyps, which can progress to malignant cancers of the colon and rectum.
  • Oral replacement therapy with human uroguanylin was used to evaluate its effects on the formation of intestinal polyps in the Min/+ mouse model for colorectal cancer.
  • Uroguanylin significantly reduces the number of polyps found in the intestine of Min/+ mice by approximately 50% of control.
  • The intestinal R-GC signaling molecules for guanylin regulatory peptides are promising targets for prevention and/or therapeutic treatment of intestinal polyps and cancers by oral administration of human uroguanylin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli / prevention & control. Apoptosis / drug effects. Colonic Neoplasms / pathology. Cyclic GMP / physiology. Gastrointestinal Hormones. Peptides / pharmacology
  • [MeSH-minor] Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Caco-2 Cells / drug effects. Down-Regulation / drug effects. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Molecular Sequence Data. Natriuretic Peptides. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Cell Surface / biosynthesis. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Tumor Cells, Cultured

  • Jackson Laboratory JAX®Mice Database. culture/stock collections - C57BL/6J-Apc<Min>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016642.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Gastrointestinal Hormones; 0 / Natriuretic Peptides; 0 / Peptides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 140653-38-9 / guanylin; 152175-68-3 / uroguanylin; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


3. Holt PR, Bresalier RS, Ma CK, Liu KF, Lipkin M, Byrd JC, Yang K: Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. Cancer; 2006 Jan 15;106(2):287-96
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa.
  • METHODS: In the current study, adenomatous polyps were transected, approximately 50% were removed for histologic examination, and the remnants tattooed before the administration of either calcium carbonate (1500 mg 3 times daily) plus vitamin D(3) 400 IU or a placebo for 6 months.
  • At study end, polyp remnants were resected completely and were used for histologic examination.
  • Immunohistochemical staining was performed in both flat mucosa and in polyp tissue.
  • RESULTS: Nineteen patients, including 11 patients in the treatment group and 8 patients in the control group, completed the study.
  • Proliferative indices fell both in flat mucosa and in polyps in the treatment group, and there were no significant changes in the control group.
  • Apoptosis and Bcl-2 immunostaining were unchanged in both groups, but the frequency of BAK-immunostained cells in the interior of polyps rose significantly.
  • Vitamin D receptor staining increased slightly and significantly in flat rectal tissue in the treatment group.
  • There were no significant changes in galectin-3 staining, but a striking reduction in MUC5AC mucin staining in polyps was observed after treatment with calcium plus vitamin D.
  • CONCLUSIONS: The administration of a calcium plus vitamin D chemopreventive regimen resulted in several changes in adenomatous tissue that may have contributed to reduced polyp formation.
  • [MeSH-major] Adenoma / drug therapy. Adenomatous Polyps / drug therapy. Calcium / administration & dosage. Colorectal Neoplasms / prevention & control. Precancerous Conditions / drug therapy. Vitamin D / administration & dosage
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Middle Aged. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353199.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01CN25439-1; United States / NCI NIH HHS / CA / R01CA69480
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  •  go-up   go-down


Advertisement
4. Terada T: Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute. Int J Clin Exp Pathol; 2009;3(2):162-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They consisted of 24 cases of gastric GIST, 1 case of hepatic GIST, 1 case of small intestinal GIST, 4 cases of colon GIST, and 1 case of rectal GIST.
  • Endoscopy and imaging modalities including US, CT and MRI were useful to detect the tumors in all cases, and biopsies confirmed the GIST diagnosis in 21 cases.
  • Grossly, 23 cases were submucosal tumors, 6 serosa-side tumors, 1 solid tumor in the liver, and 1 rectal polyp.
  • Histologically, 28 cases were of spindle cell type and 3 of epithelioid type.
  • The chemotherapy was imatinib mesylate in 6 cases, and none in 25 cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7256-9 [19084944.001]
  • [Cites] Med Oncol. 2009;26(2):233-7 [18777214.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1606-8 [14632569.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):29-34 [19047911.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • (PMID = 20126584.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Codon; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC2809996
  • [Keywords] NOTNLM ; GIST / KIT / PDGFRA / clinicopathology / desmin / genetics / immunohisology
  •  go-up   go-down


5. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R: Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res; 2010 Mar 15;70(6):2368-78
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Silibinin feeding strongly prevented intestinal tumorigenesis in terms of polyp formation in proximal, middle, and distal portions of small intestine by 27% (P < 0.001), 34% (P < 0.001), and 49% (P < 0.001), respectively.
  • In colon, we observed 55% (P < 0.01) reduction in number of polyps by silibinin treatment.
  • In size distribution analysis, silibinin showed significant decrease in large-size polyps (>3 mm) by 66% (P < 0.01) and 88% (P < 0.001) in middle and distal portions of small intestine, respectively.
  • More importantly, silibinin caused a complete suppression in >3 mm sized polyps and 92% reduction in >2 to 3 mm sized polyps in colon.
  • Molecular analyses of polyps suggested that silibinin exerts its chemopreventive efficacy by inhibiting cell proliferation, inflammation, and angiogenesis; inducing apoptosis; decreasing beta-catenin levels and transcriptional activity; and modulating the expression profile of cytokines.
  • These results show for the first time the efficacy and associated mechanisms of long-term p.o. silibinin feeding against spontaneous intestinal tumorigenesis in the APC(min/+) mice model, suggesting its chemopreventive potential against intestinal cancers including CRC.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Integr Cancer Ther. 2007 Jun;6(2):104-9 [17548789.001]
  • [Cites] J BUON. 2006 Apr-Jun;11(2):213-6 [17318973.001]
  • [Cites] Cancer Biomark. 2007;3(4-5):263-74 [17917155.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2525-38 [17938238.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9937-44 [17942926.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):350-9 [17184801.001]
  • [Cites] J Cell Biochem. 2007 Nov 1;102(4):820-8 [17854061.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):300-8 [18172282.001]
  • [Cites] J Pathol. 2008 Feb;214(3):294-301 [18085615.001]
  • [Cites] Crit Rev Clin Lab Sci. 2008;45(3):291-338 [18568853.001]
  • [Cites] Pathol Res Pract. 2008;204(7):501-10 [18541387.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6822-30 [18701508.001]
  • [Cites] Immunobiology. 2008;213(9-10):733-49 [18926289.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6194-206 [18931687.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7773-80 [19047104.001]
  • [Cites] Cell Tissue Res. 2009 Jan;335(1):261-9 [18766380.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):376-84 [19138982.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):74-83 [19139021.001]
  • [Cites] J Cell Sci. 1998 Jul 30;111 ( Pt 14):1951-61 [9645943.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5439-47 [15331580.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1969-79 [16084079.001]
  • [Cites] Int J Biochem Cell Biol. 2006 Mar;38(3):333-57 [16309946.001]
  • [Cites] Expert Opin Pharmacother. 2009 Feb;10(2):211-9 [19236194.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2043-50 [18339887.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Curr Drug Targets. 2008 May;9(5):375-80 [18473765.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2101-8 [10545412.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1167-73 [10613309.001]
  • [Cites] Chest. 2000 Apr;117(4):1162-72 [10767254.001]
  • [Cites] BioDrugs. 2001;15(7):465-89 [11520257.001]
  • [Cites] FASEB J. 2002 Jan;16(1):2-14 [11772931.001]
  • [Cites] Life Sci. 2002 Feb 8;70(12):1447-59 [11883719.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):120-7 [12542982.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] J Cell Sci. 2003 Aug 1;116(Pt 15):3051-60 [12829735.001]
  • [Cites] Urol Res. 2003 Aug;31(4):232-5 [12937869.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8271-82 [14614451.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):5-6 [14749120.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Dis Colon Rectum. 1992 Dec;35(12):1170-3 [1335405.001]
  • [Cites] Dis Colon Rectum. 1993 Nov;36(11):1059-62 [8223060.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):6-8 [16413466.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3065-70 [16407833.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7370-7 [16849589.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):373-85 [17006765.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):147-54 [17164142.001]
  • [Cites] Int J Oncol. 2007 Mar;30(3):593-603 [17273760.001]
  • [Cites] Subcell Biochem. 2007;42:93-126 [17612047.001]
  • (PMID = 20215518.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112304-05; United States / NCI NIH HHS / CA / R01 CA112304; United States / NCI NIH HHS / CA / R01 CA112304-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Silymarin; 0 / beta Catenin; 136601-57-5 / Cyclin D1; 4RKY41TBTF / silybin; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS172766; NLM/ PMC2840193
  •  go-up   go-down


6. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW: Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology; 2004 Feb;126(2):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
  • BACKGROUND & AIMS: Familial adenomatous polyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by development of colorectal adenomas and, ultimately, colorectal cancer.
  • The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemoprevention with the nonsteroidal anti-inflammatory drug sulindac was evaluated.
  • METHODS: A randomized, double-blind, placebo-controlled study of 41 subjects genotypically affected with familial adenomatous polyposis but phenotypically unaffected was conducted.
  • The levels of 5 prostanoids, ornithine decarboxylase, and polyamines were measured serially in normal-appearing rectal mucosa.
  • RESULTS: There were no statistically significant differences between treatment groups in baseline levels of prostanoids, ornithine decarboxylase, or polyamines.
  • Among the subset of patients taking sulindac, 3 of 5 prostaglandin levels were statistically significantly lower in patients who were polyp free than in those who developed polyps.
  • By contrast, there were no statistically significant differences in ornithine decarboxylase or polyamines between treatment groups or in those on sulindac who were polyp free compared with those who developed polyps.
  • CONCLUSIONS: Colorectal mucosal prostaglandin levels, but not ornithine decarboxylase or polyamines, may be valuable biomarkers to assess appropriate drug dosage and medication compliance in patients undergoing primary chemoprevention therapy with sulindac.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Nov;44(11):4924-8 [6488154.001]
  • [Cites] Cell. 1991 Aug 9;66(3):601-13 [1678319.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4449-52 [3731101.001]
  • [Cites] J Chromatogr. 1986 Jul 11;380(1):19-32 [3745383.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1275-81 [3621111.001]
  • [Cites] Ann Surg. 1988 Jun;207(6):662-9 [3389934.001]
  • [Cites] J Surg Oncol. 1988 Aug;38(4):240-3 [3411968.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):639-43 [2535963.001]
  • [Cites] J Natl Cancer Inst. 1989 Mar 15;81(6):421-7 [2493096.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1061-6 [2758383.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4528-34 [1831401.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):369-74 [8348060.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Gut. 1994 May;35(5):675-8 [8200564.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):813-30 [7634976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):37-48 [8993796.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):199-201 [9000553.001]
  • [Cites] Dig Dis Sci. 1998 Feb;43(2):311-6 [9512123.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1750-3 [9563494.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2000 Jan;60(1-3):83-96 [10680778.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Scand J Gastroenterol. 2001 Aug;36(8):865-9 [11495083.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2069-72 [2009526.001]
  • [Cites] Dis Colon Rectum. 1991 Jul;34(7):572-6 [2055143.001]
  • [Cites] Histochem Cell Biol. 2001 Aug;116(2):171-81 [11685545.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Am J Physiol. 1982 Nov;243(5):C212-21 [6814260.001]
  • [Cites] J Surg Oncol. 1983 Sep;24(1):83-7 [6887943.001]
  • [Cites] Methods Enzymol. 1983;94:158-61 [6621384.001]
  • [Cites] N Engl J Med. 1984 Jul 12;311(2):80-3 [6738598.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3226-30 [6430547.001]
  • [Cites] Br J Surg. 1984 Oct;71(10):791-4 [6487981.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):117-20 [2062082.001]
  • [Cites] Gastroenterology. 1991 Sep;101(3):635-9 [1650315.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):89-93 [3729588.001]
  • (PMID = 14762779.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R24 DK064399-01; United States / NIDDK NIH HHS / DK / DK064399-01; United States / NCI NIH HHS / CA / CA 51085; United States / NCI NIH HHS / CA / CA 53801; United States / NIDDK NIH HHS / DK / R24 DK064399; United States / NCI NIH HHS / CA / CA 63721; United States / NCI NIH HHS / CA / P50 CA 93-16
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Polyamines; 0 / Prostaglandins; 184SNS8VUH / Sulindac; EC 4.1.1.17 / Ornithine Decarboxylase
  • [Other-IDs] NLM/ NIHMS38268; NLM/ PMC2225536
  •  go-up   go-down


7. Khosraviani K, Weir HP, Hamilton P, Moorehead J, Williamson K: Effect of folate supplementation on mucosal cell proliferation in high risk patients for colon cancer. Gut; 2002 Aug;51(2):195-9
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to determine the effect of folate supplementation on patients with recurrent adenomatous polyps using rectal mucosal cell proliferation as a biomarker.
  • PATIENTS AND METHODS: Eleven patients with recurrent adenomatous polyps of the colon were randomised into a treatment group (n=6) receiving a dietary supplement of 2 mg folic acid per day for three months and a control group (n=5) receiving a placebo.
  • Rectal biopsies where taken at 10 cm from the anal verge prior to supplementation and repeated at four, 12, and 18 weeks from the start of the supplementation.
  • The S phase cells which incorporated BrdU into their DNA were identified following immunohistochemical staining.
  • Twenty five orientated crypts were identified for each time point and the number and position of BrdU positive and BrdU negative cells were counted.
  • RESULTS: The LI of the treatment group (9.1 (6.7, 12.3)) and the control group (9.3 (7.8, 10.3)) were comparable at the start.
  • [MeSH-major] Colonic Neoplasms / prevention & control. Colonic Polyps / drug therapy. Dietary Supplements. Folic Acid / administration & dosage. Intestinal Mucosa / cytology
  • [MeSH-minor] Cell Division / drug effects. Erythrocytes / chemistry. Humans. Rectum. Recurrence. Risk. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 1999 Feb;81(2):181-8 [9927538.001]
  • [Cites] Gut. 1998 Jul;43(1):93-9 [9771411.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5002-6 [1516055.001]
  • [Cites] Gut. 1992 Nov;33(11):1528-31 [1452078.001]
  • [Cites] Eur J Cancer Prev. 1992 Aug;1(5):381-3 [1463991.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] Am J Epidemiol. 1993 Aug 15;138(4):225-36 [8395140.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):213-9 [8370618.001]
  • [Cites] Adv Enzyme Regul. 1980;19:295-308 [7337030.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Science. 1985 Apr 12;228(4696):187-90 [2579435.001]
  • [Cites] Gastroenterology. 1987 Mar;92(3):704-8 [3817391.001]
  • [Cites] Gastroenterology. 1987 Apr;92(4):1083-6 [3549422.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):235-45 [3275494.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Nature. 1989 Mar 30;338(6214):389-94 [2648156.001]
  • [Cites] Cancer Lett. 1990 Aug;53(1):17-25 [2397478.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):873-8 [1855187.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):161-7 [1652565.001]
  • [Cites] Eur J Cancer Prev. 1994 Nov;3(6):473-9 [7858479.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):265-73 [7707417.001]
  • [Cites] Curr Opin Genet Dev. 1995 Feb;5(1):72-8 [7749329.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):709-14 [8672986.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11):1727-36, 1742-3; discussion 1743-4 [8953590.001]
  • [Cites] Am J Clin Nutr. 1997 Jan;65(1):46-52 [8988912.001]
  • [Cites] Am J Clin Nutr. 1997 Jan;65(1 Suppl):196S-210S [8988938.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):469-71 [9184782.001]
  • [Cites] Epidemiology. 1997 Nov;8(6):658-65 [9345666.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):670-7 [9398044.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] Ann Intern Med. 1998 Oct 1;129(7):517-24 [9758570.001]
  • [Cites] Int J Epidemiol. 1991 Jun;20(2):368-74 [1917236.001]
  • (PMID = 12117879.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ PMC1773332
  •  go-up   go-down


8. Gence A, Sahin C, Celayir AC, Yavuz H: Primary Burkitt lymphoma presenting as a solitary rectal polyp in a child. Pediatr Surg Int; 2008 Nov;24(11):1215-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma presenting as a solitary rectal polyp in a child.
  • Primary rectal lymphoma in childhood is extremely rare.
  • This report focuses on the importance of considering the possibility of malignancy in rectal polyps.
  • We report a 5-year-old girl with fresh rectal bleeding who was admitted in our clinic.
  • In physical exam, we found a single pedicled polyp on the posterior wall of the rectum.
  • Surgical removal under general anesthesia involved polyp and its pedicle.
  • Histopathological examination and immunohistochemistry study of the polyp revealed a high-grade B-cell lymphoma (Burkitt lymphoma).
  • The patient was referred to pediatric oncology center for chemotherapy.
  • Primary rectal lymphoma in childhood is extremely rare; therefore, the possibility of malignancy in rectal polyps should be considered in the pediatric patients.
  • [MeSH-major] Burkitt Lymphoma / surgery. Intestinal Polyps / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 1989;19(6-7):474-6 [2771496.001]
  • [Cites] Arch Pediatr. 2002 Oct;9(10):1056-8 [12462838.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Pediatr Dev Pathol. 2003 Mar-Apr;6(2):182-6 [12522693.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Aug;31(2):193-4 [10941976.001]
  • [Cites] J Pediatr Surg. 1997 Jul;32(7):1004-8; discussion 1008-9 [9247222.001]
  • [Cites] J Pediatr Surg. 1990 Dec;25(12):1280-2 [2286908.001]
  • [Cites] Indian Pediatr. 1981 Nov;18(11):835-7 [7341479.001]
  • [Cites] Clin Radiol. 1994 Sep;49(9):594-600 [7955884.001]
  • (PMID = 18810465.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Kuhne HP, Göller T, Schneider I, Bozkurt T, Becker HP: [Unclear per anum bleeding during pregnancy]. Chirurg; 2005 Aug;76(8):765-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rectoscopy showed the cause to be a polyp the size of a fingertip 9 cm from the anus.
  • Seeking a prognosis optimal for the newborn child, the interdisciplinary decision was made for primary surgery with adjuvant chemotherapy.
  • [MeSH-major] Intestinal Polyps / diagnosis. Melena / etiology. Neuroendocrine Tumors / diagnosis. Pregnancy Complications / etiology. Pregnancy Complications, Neoplastic / diagnosis. Puerperal Disorders / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Disease Progression. Female. Humans. Infant, Newborn. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Rectum / pathology. Rectum / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Jun;48(2):150-63 [15243410.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):95-7 [10778777.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Am J Surg Pathol. 1990 Nov;14(11):1010-23 [2173427.001]
  • [Cites] Drug Saf. 1998 Feb;18(2):135-42 [9512920.001]
  • (PMID = 15971036.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Floyd ND, Saclarides TJ: Transanal endoscopic microsurgical resection of pT1 rectal tumors. Dis Colon Rectum; 2006 Feb;49(2):164-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgical resection of pT1 rectal tumors.
  • This study will show that transanal endoscopic microsurgical treatment of pT1 rectal cancers is safe and achieves low local recurrence and high survival rates.
  • METHODS: Retrospective review performed of all pT1 rectal cancers treated by a single surgeon (TS) using transanal endoscopic microsurgery between 1991 and 2003.
  • Patient age, gender, tumor distance from the anal verge, lesion size, operative time, blood loss, complications, recurrence, and survival rates were prospectively recorded.
  • Radiation and/or chemotherapy were not administered.
  • Sixteen patients had pT1 lesions removed piecemeal during colonoscopy; there was no residual tumor after transanal endoscopic microsurgical resection of the polyp site.
  • CONCLUSIONS: Transanal endoscopic microsurgical resection of pT1 rectal cancers yields low recurrence rates.
  • [MeSH-major] Neoplasm Recurrence, Local. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362801.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Chmiel B, Nocoń G: [Secondary primary, bilocal sigmoid colon adenocarcinoma in a patient previously treated for testicular cancer]. Wiad Lek; 2004;57(5-6):288-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent nearly total colectomy and resection of the rectal polyp.
  • This case is an illustration of the problem of cancerogenesis within polyps of the large bowel in patients treated before by chemotherapy because of testicular cancer.
  • [MeSH-major] Adenocarcinoma. Neoplasms, Second Primary. Rectal Neoplasms. Sigmoid Neoplasms. Testicular Neoplasms
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518079.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Solaz Moreno E, Vallalta Morales M, Silla Búrdalo G, Cervera Miguel JI, Díaz Beveridge R, Rayón Martín JM: [Primary melanoma of the rectum: an infrequent neoplasia with an atypical presentation]. Clin Transl Oncol; 2005 May;7(4):171-3
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary melanoma of the rectum: an infrequent neoplasia with an atypical presentation].
  • The main clinical presentations are local symptoms such as rectal bleeding, anal mass or pain, or a change in bowel habits.
  • The tumour is frequently mistaken for benign conditions as haemorrhoids or rectal polyps.
  • Many treatments can be used: surgery, chemotherapy, radiotherapy, immunotherapy and even bio-therapy.
  • [MeSH-major] Melanoma / diagnosis. Rectal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2205-11 [14640919.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Eur J Surg. 2000 Jul;166(7):583-4 [10965842.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Sep;12(9):1545-58 [12943498.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • (PMID = 15960927.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Stănciulea O, Preda C, Herlea V, Popa M, Ulmeanu D, Vasilescu C: [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis]. Chirurgia (Bucur); 2007 Mar-Apr;102(2):215-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis].
  • We present the case of a 52 years old man, with significant familial history, diagnosed with familial adenomatous polyposis-attenuated form, with no clinical and endoscopic surveillance until 2001 when he was admitted for an upper gastrointestinal haemorrhage episode.
  • Upper gastrointestinal scopy revealed duodenal adenomatous polyps and gastric hyperplastic polyps.
  • The histopathological exam revealed duodenal G2 adenocarcinoma pT3N0, and gastric hyperplastic polyps with no signs of dysplasia.
  • The surgical procedure was followed by chemotherapy.
  • In 2002 the patient was admitted for rectal bleeding and colonoscopy showed 2 sigmoid polyps, appropriate for endoscopic removal and a poly-lobate polyp in the transverse colon.
  • March 2003--the patient underwent endoscopic removal for a rectal polyp (histopathological exam: moderate dysplasia).
  • Intraoperatively were noted: peritoneal carcinomatosis and multiple liver metastasis.
  • The surgical procedure recommended in patients with attenuated form of familial adenomatous polyposis and suspect periampullary lesions is duodenopancreatectomy.
  • The particularity of the case is the association of total gastrectomy for gastric hyperplastic polyps.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Carcinoma / surgery. Duodenal Neoplasms / surgery. Gastrectomy. Neoplasms, Multiple Primary / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Ampulla of Vater. Humans. Male. Middle Aged. Stomach Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615925.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


14. Zakharash MP, Poĭda OI: [Application of preparations relief ultra and relief advance in practice of coloproctological department]. Klin Khir; 2005 Oct;(10):9-12
Hazardous Substances Data Bank. ZINC SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy of application of preparations Relief Ultra and Relief Advance as pathogenetically directed medicines was established, basing on analysis of the examination and treatment results in 133 patients with anal region diseases (acute and chronic hemorrhoids, nonspeciphic ulcerative colitis, the Crohn's disease, acute paraproctitis, rectal polyp).
  • For local conservative treatment it is expedient to apply preparations in various pharmacological forms in complex.
  • Application of preparation Relief Ultra endorectally in conjunction with preparation Relief Advance endorectally and locally on the wound surface is indicated after performance of elective and urgent operative interventions for rectal and anal zone diseases.

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509076.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fish Oils; 0 / Suppositories; 3X7931PO74 / hydrocortisone acetate; 7733-02-0 / Zinc Sulfate; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


15. Ben-Josef E, Han S, Tobi M, Shaw LM, Bonner HS, Vargas BJ, Prokop S, Stamos B, Kelly L, Biggar S, Kaplan I: A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys; 2002 Aug 1;53(5):1160-4
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
  • PURPOSE: Clinical symptomatic late injury to the rectal wall occurs in about one-third of patients with prostate cancer treated with external beam irradiation.
  • Reducing the physical dose to the anterior rectal wall without a similar reduction in the posterior peripheral zone is difficult because of the proximity of the prostate to the anterior rectal wall.
  • On the basis of our previous observations in an animal model that intrarectal application of amifostine resulted in very high concentrations of amifostine and its active metabolite WR-1065 in the rectal wall, a Phase I dose-escalation clinical trial was undertaken.
  • The total dose to the prostate was 70.2 Gy in 20 patients and 73.8 Gy in 9 patients.
  • Therapy was delivered using a 4-field technique with three-dimensional conformal planning.
  • Amifostine was administered intrarectally as an aqueous solution 30 min before irradiation on the first 15 days of therapy.
  • Proctoscopy was performed before therapy and at 9 months after completion.
  • The clinical symptoms (Radiation Therapy Oncology Group scale) and a proctoscopy score were assessed during follow-up.
  • RESULTS: All patients completed therapy with no amifostine-related toxicity at any dose level.
  • With a median follow-up of 26 months, 9 patients (33%) developed rectal bleeding (8 Grade 1, 1 Grade 2).
  • At 9 months, 16 and 3 patients developed Grade 1 and Grade 2 telangiectasia, respectively.
  • This was mostly confined to the anterior rectal wall.
  • Four patients (14%) developed symptoms suggestive of radiation damage that, on sigmoidoscopy, proved to be secondary to unrelated processes.
  • These included preexisting nonspecific proctitis (n = 1), diverticular disease of the sigmoid colon (n = 1), rectal polyp (n = 1), and ulcerative colitis (n = 1).
  • Symptoms developed significantly more often in patients receiving 500-1000 mg than in patients receiving 1500-2500 mg amifostine (7 [50%] of 14 vs. 2 [15%] of 13, p = 0.0325, one-sided chi-square test).
  • Systemic absorption of amifostine and its metabolites is negligible, and close monitoring of patients is not required with rectal administration.
  • Proctoscopy is superior to symptom score as a method of assessing radiation damage of the rectal wall.
  • [MeSH-minor] Administration, Topical. Amifostine / administration & dosage. Amifostine / pharmacology. Analysis of Variance. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Humans. Intestines / metabolism. Male. Mercaptoethylamines / pharmacology. Multivariate Analysis. Radiation-Protective Agents / pharmacology. Rectum / pathology. Rectum / radiation effects. Telangiectasis / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12128116.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mercaptoethylamines; 0 / Radiation-Protective Agents; 31098-42-7 / WR 1065; M487QF2F4V / Amifostine
  •  go-up   go-down


16. Akasu T, Yokoyama T, Sugihara K, Fujita S, Moriya Y, Kakizoe T: Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study. Hepatogastroenterology; 2002 Sep-Oct;49(47):1259-61
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study.
  • BACKGROUND/AIMS: The efficacy of peroral sustained-release indomethacin on rectal adenomas in colectomized patients with familial adenomatous polyposis and its toxicity were evaluated preliminarily.
  • METHODOLOGY: A total of seven colectomized patients with familial adenomatous polyposis were treated with peroral sustained-release indomethacin at the usual clinical doses.
  • The numbers of rectal polyps before and after treatment and approximately one year after cessation of treatment were counted using a flexible colonoscope and compared.
  • RESULTS: After treatment, reductions of rectal polyp size were observed in all patients.
  • Numbers of the rectal polyps also decreased significantly after treatment (median, 1; range, 0 to 30) compared with those before treatment (median, 19; range, 4 to 78) (P = 0.023).
  • Moreover, one year after termination of the treatment, increase in the size and number of rectal polyps was observed in six patients.
  • CONCLUSIONS: Because of incomplete efficacy and severe toxicity, general use of this treatment for familial adenomatous polyposis patients must be deemed inappropriate.
  • [MeSH-major] Adenoma / drug therapy. Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Indomethacin / administration & dosage. Neoplasms, Multiple Primary / drug therapy. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12239919.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Delayed-Action Preparations; XXE1CET956 / Indomethacin
  •  go-up   go-down


17. Tonelli F, Valanzano R, Messerini L, Ficari F: Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol; 2000 May;74(1):15-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
  • BACKGROUND AND OBJECTIVES: Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP).
  • Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma remain unclear.
  • Number, size, and type of rectal polyps were assessed by endoscopic and histological evaluation every 6 months.
  • RESULTS: Significant regression of polyps was observed in all patients after 6 months (P < 0.02).
  • However, after a mean of 48.6 +/- 28.7 months, both number and size of polyps increased again, showing no statistical difference with baseline values.
  • Minute polyps appeared reddish, while the largest lesions were flat or slightly elevated.
  • Two patients were submitted to restorative proctectomy because of a large polyp with severe dysplasia and a rectal cancer, respectively.
  • CONCLUSIONS: Sulindac appears to influence the morphological appearance of polyps in FAP patients, inducing apparent regression.
  • However, at a dose of 200 mg, it does not influence the progression of polyps toward a malignant pattern.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Rectal Neoplasms / prevention & control. Sulindac / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Colorectal Neoplasms / pathology. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Proctocolectomy, Restorative

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10861602.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac
  •  go-up   go-down


18. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet; 2009 May 9;373(9675):1607-14
MedlinePlus Health Information. consumer health - Diabetes Type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
  • BACKGROUND: The increased prevalence of type 2 diabetes mellitus is a major concern for health providers.
  • We therefore assessed whether voglibose, an alpha-glucosidase inhibitor, could prevent the development of type 2 diabetes in high-risk Japanese individuals with impaired glucose tolerance.
  • METHODS: 1780 eligible patients on a standard diet and taking regular exercise with impaired glucose tolerance were randomly assigned to oral voglibose 0.2 mg three times a day (n=897) or placebo (n=883) in a multicentre, double-blind, parallel group trial.
  • Treatment was continued until participants developed type 2 diabetes (primary endpoint) or normoglycaemia (secondary endpoint), or for a minimum of 3 years, subject to the findings of an interim analysis.
  • Patients treated with voglibose had a lower risk of progression to type 2 diabetes than did those on placebo (50 of 897 vs 106 of 881; hazard ratio 0.595, 95% CI 0.433-0.818; p=0.0014).
  • Serious adverse events (all one each) in the voglibose group were cholecystitis, colonic polyp, rectal neoplasm, inguinal hernia, liver dysfunction, and subarachnoid haemorrhage, and in the placebo group were cerebral infarction and cholecystitis.
  • INTERPRETATION: Voglibose, in addition to lifestyle modification, can reduce the development of type 2 diabetes in high-risk Japanese individuals with impaired glucose tolerance.
  • [MeSH-major] Diabetes Mellitus, Type 2 / prevention & control. Glucose Intolerance / drug therapy. Hypoglycemic Agents / therapeutic use. Inositol / analogs & derivatives

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • Genetic Alliance. consumer health - Diabetes mellitus type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2009 May 9;373(9675):1579-80 [19395080.001]
  • [CommentIn] Lancet. 2009 Aug 8;374(9688):448-9 [19665640.001]
  • [CommentIn] Lancet. 2009 Aug 8;374(9688):448 [19665639.001]
  • (PMID = 19395079.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoside Hydrolase Inhibitors; 0 / Hypoglycemic Agents; 4L6452S749 / Inositol; 83480-29-9 / voglibose
  •  go-up   go-down


19. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1035-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.
  • BACKGROUND & AIMS: Familialadenomatous polyposis (FAP) is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual colorectal cancer.
  • Regression of adenomas in this syndrome occurs with the administration of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, but these compounds can have considerable side effects.
  • METHODS: Five FAP patients with prior colectomy (4 with retained rectum and 1 with an ileal anal pouch) received curcumin 480 mg and quercetin 20 mg orally 3 times a day.
  • The number and size of polyps were assessed at baseline and after therapy.
  • The Wilcoxon signed-rank test was used to determine differences in the number and size of polyps.
  • Treatment side effects and medication compliance also were evaluated.
  • RESULTS: All 5 patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment with curcumin and quercetin.
  • The mean percent decrease in the number and size of polyps from baseline was 60.4% (P < .05) and 50.9% (P < .05), respectively.
  • CONCLUSIONS: The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Antineoplastic Agents / therapeutic use. Antioxidants / therapeutic use. Curcumin / therapeutic use. Quercetin / therapeutic use
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Sigmoidoscopy

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757216.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 53801; United States / NCI NIH HHS / CA / K07 CA092445; United States / NCI NIH HHS / CA / P50 CA 62924-10
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 9IKM0I5T1E / Quercetin; IT942ZTH98 / Curcumin
  •  go-up   go-down


20. Shia J, Teruya-Feldstein J, Pan D, Hegde A, Klimstra DS, Chaganti RS, Qin J, Portlock CS, Filippa DA: Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol; 2002 Feb;26(2):216-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of four cases showed cytogenetic or molecular genetic evidence of t(14;18).
  • Initial treatment modalities included surgery plus chemotherapy (nine cases), surgery alone (seven cases), chemotherapy alone (four cases), observation alone (four cases), and chemotherapy and abdominal radiation (one case).
  • One case presented with rectal polyps and was treated with polypectomy.
  • A complete response was observed in 15 of 22 cases that received treatment, and of the 15 cases, five recurred 27-60 months after the initial diagnosis.
  • No significant correlation was identified between treatment response and various clinical and pathologic features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Cytogenetics. Digestive System Surgical Procedures. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11812943.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Franklin ME Jr, Díaz-E JA, Abrego D, Parra-Dávila E, Glass JL: Laparoscopic-assisted colonoscopic polypectomy: the Texas Endosurgery Institute experience. Dis Colon Rectum; 2000 Sep;43(9):1246-9
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the more common procedures of colorectal surgery is segmental resection for polyps that are large, broad based, or inaccessible for colonoscopic removal.
  • We present a technique combining colonoscopy and laparoscopy to remove troublesome polyps without the need for segmental resections.
  • METHODS: From May 1990 to September 1999 laparoscopic-monitored colonic polypectomies were performed in 47 patients, with a total of 60 polyps being removed.
  • The polyp is then presented to the colonoscopist by the laparoscopist facilitating removal.
  • All polyps undergo immediate frozen section analysis.
  • If the pathologic evaluation indicates malignancy then a segmental resection may be performed, otherwise the patients are decompressed and fed within a short time before discharge.
  • RESULTS: The polyps were located most commonly in the ascending colon (18 polyps), transverse colon (12 polyps), and cecum (12 polyps).
  • The most common histopathologic diagnosis was tubulovillous adenoma in 28 polyps followed by villous adenoma in 11 polyps.
  • In three cases histopathologic diagnosis revealed malignancy necessitating segmental resection (1 low anterior resection and 2 right hemicolectomies), which were performed laparoscopically.
  • CONCLUSION: Laparoscopic-monitored colonoscopic polypectomy allows patients to undergo removal of colonic polyps without a segmental resection.
  • This less invasive procedure yields recovery times similar to that of colonoscopy alone, and the potential complications of a segmental resection are avoided.
  • All polyps are examined by frozen section, and if a malignancy is encountered, a laparoscopic resection can be performed.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Laparoscopy / methods
  • [MeSH-minor] Acetaminophen / therapeutic use. Adenoma, Villous / surgery. Aged. Analgesics, Non-Narcotic / therapeutic use. Colonic Neoplasms / surgery. Female. Humans. Male. Pain, Postoperative / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005491.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


22. Knottenbelt CM, Simpson JW, Tasker S, Ridyard AE, Chandler ML, Jamieson PM, Welsh EM: Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract; 2000 Sep;41(9):393-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps.
  • Rectal tubulopapillary polyps were diagnosed in eight dogs following proctoscopy and mucosal pinch biopsy.
  • The remaining cases were diagnosed as benign polyps.
  • All dogs were re-examined after four to six weeks of piroxicam therapy and the extent of haematochezia, tenesmus and faecal mucus production was reduced in all cases.
  • Medical management with piroxicam may provide a non-invasive treatment option for dogs with rectal polyp formation in which surgical treatment is likely to be associated with complications such as incontinence, infection and wound breakdown, or where the owner declines such treatment.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Intestinal Polyps / drug therapy. Intestinal Polyps / veterinary. Piroxicam / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / veterinary
  • [MeSH-minor] Animals. Apoptosis. Cell Cycle. Dogs. Female. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11023124.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam
  •  go-up   go-down


23. Bese T, Simsek Y, Bese N, Ilvan S, Arvas M: Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer; 2003 May-Jun;13(3):376-80
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 74-year-old woman with a history of breast carcinoma who received tamoxifen therapy for 2 years was admitted with uterine bleeding.
  • Hysteroscopic polypectomy revealed a hyperplastic polyp.
  • The cervix, rectum, and the accompanying mass were resected.
  • Histopathologic examination revealed endocervical adenocarcinoma and endometriosis involving cervix uteri and the rectal muscular wall.
  • As cervical cancer occurred in a short period, it might be speculated that tamoxifen might have stimulated the proliferative and mitotic activity of cervical endometrial tissue which has progressed into invasive cancer in time.
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Pelvis. Postmenopause


24. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology; 2002 Mar;122(3):641-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
  • BACKGROUND & AIMS: Management of patients with familial adenomatous polyposis (FAP) can consist of colectomy with ileorectal anastomosis (IRA).
  • Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients, although long-term use of this therapy has not been studied.
  • We evaluated the long-term effectiveness and toxicity of sulindac in attempting to maintain retained rectal segments free of adenomas.
  • Number, size, and histologic grade of polyps, side effects, and medication compliance were assessed every 4 months.
  • RESULTS: Seven of 12 patients (58%) remained in the study (6 of these polyp-free) for a mean of 76.9 +/- 27.5 months.
  • A significant regression of polyp number was observed in all patients at 12 months (P = 0.039) and at a mean of 63.4 +/- 31.3 months (P = 0.006).
  • At 35 months of follow-up, 1 patient developed stage III cancer in the rectal stump.
  • The most common side effect was rectal mucosal erosions in 6 patients.
  • CONCLUSIONS: Long-term use of sulindac seems to be effective in reducing polyp number and preventing recurrence of higher-grade adenomas in the retained rectal segment of most FAP patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Sulindac / administration & dosage
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Rectum / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874996.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac
  •  go-up   go-down


25. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, Gail MH, Pfeiffer RM: Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol; 2009 Feb 10;27(5):686-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The development of separate CRC absolute risk models for men and women included estimating relative risks and attributable risk parameters from population-based case-control data separately for proximal, distal, and rectal cancer and combining these estimates with baseline age-specific cancer hazard rates based on Surveillance, Epidemiology, and End Results (SEER) incidence rates and competing mortality risks.
  • RESULTS: For men, the model included a cancer-negative sigmoidoscopy/colonoscopy in the last 10 years, polyp history in the last 10 years, history of CRC in first-degree relatives, aspirin and nonsteroidal anti-inflammatory drug (NSAID) use, cigarette smoking, body mass index (BMI), current leisure-time vigorous activity, and vegetable consumption.
  • For women, the model included sigmoidoscopy/colonoscopy, polyp history, history of CRC in first-degree relatives, aspirin and NSAID use, BMI, leisure-time vigorous activity, vegetable consumption, hormone-replacement therapy (HRT), and estrogen exposure on the basis of menopausal status.
  • CONCLUSION: We developed absolute risk prediction models for CRC from population-based data, and a simple questionnaire suitable for self-administration.
  • [MeSH-minor] Aged. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Body Mass Index. Colonoscopy. Diet. European Continental Ancestry Group. Female. Humans. Intestinal Polyps. Leisure Activities. Male. Middle Aged. Models, Theoretical. Proportional Hazards Models. Risk Factors. Sigmoidoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Ann Epidemiol. 1997 Feb;7(2):137-45 [9099401.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):715-23 [15900041.001]
  • [Cites] Biometrics. 2005 Sep;61(3):847-55 [16135037.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3590-6 [16728488.001]
  • [Cites] Am J Med. 2007 Mar;120(3):257-63 [17349449.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):715-26 [17470739.001]
  • [Cites] Am J Epidemiol. 2007 Oct 1;166(7):832-40 [17670910.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4974-81 [17971596.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1782-92 [18042936.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):694-8 [19114700.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):477-88 [10880030.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):555-63 [10880038.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):278-83 [12147370.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):925-43 [12489270.001]
  • [Cites] Nutr Cancer. 2002;43(2):121-6 [12588690.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):470-8 [12644540.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):75-84 [12708728.001]
  • [Cites] Ann Intern Med. 2003 Dec 16;139(12):959-65 [14678915.001]
  • [Cites] Nutr Cancer. 2003;46(2):166-71 [14690792.001]
  • [Cites] Am J Epidemiol. 2004 Jan 1;159(1):32-41 [14693657.001]
  • [Cites] Am J Clin Nutr. 2004 Feb;79(2):274-81 [14749234.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 [14759989.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Sports Med. 2004;34(4):239-52 [15049716.001]
  • [Cites] Am J Epidemiol. 1989 Sep;130(3):522-9 [2763997.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] J Natl Cancer Inst. 1991 Sep 18;83(18):1324-9 [1886158.001]
  • [Cites] Ann Intern Med. 1993 May 15;118(10):785-90 [8470852.001]
  • [Cites] Breast Cancer Res Treat. 1993 Nov;28(2):115-20 [8173064.001]
  • [Cites] N Engl J Med. 1994 Dec 22;331(25):1669-74 [7969357.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1717-30 [8944002.001]
  • [Cites] Int J Cancer. 1997 Jan 27;70(3):259-64 [9033624.001]
  • [Cites] Cancer Causes Control. 1999 Jun;10(3):167-80 [10454062.001]
  • (PMID = 19114701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Other-IDs] NLM/ PMC2645090
  •  go-up   go-down


26. Wallace MH, Forbes A, Beveridge IG, Spigelman AD, Hewer A, Venitt S, Phillips RK: Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum; 2001 Nov;44(11):1585-9
Hazardous Substances Data Bank. RANITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis.
  • PURPOSE: Bile has been implicated in the pathogenesis of duodenal polyps in patients with familial adenomatous polyposis.
  • In vitro experiments have shown that familial adenomatous polyposis bile is capable of producing DNA adducts.
  • The aim of this double-blind randomized placebo-controlled trial was to examine the effect of oral ranitidine on duodenal polyposis in a group of patients with familial adenomatous polyposis.
  • METHODS: Twenty-six patients with familial adenomatous polyposis were randomly assigned to ranitidine 300 mg daily or placebo for six months after baseline endoscopy.
  • Polyp counts were performed and biopsy specimens taken to detect DNA adducts by 32P-postlabeling.
  • RESULTS: No difference was seen in polyp numbers (P = 0.9) or relative adduct labeling (P = 0.7) after treatment with ranitidine or placebo.
  • DISCUSSION: Acid suppression therapy does not seem to improve duodenal polyposis despite in vitro findings.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Ulcer Agents / pharmacology. DNA Adducts. Duodenal Neoplasms / drug therapy. Intestinal Polyps / drug therapy. Ranitidine / pharmacology
  • [MeSH-minor] Administration, Oral. Adult. Bile / chemistry. Double-Blind Method. Endoscopy. Female. Gastric Acid. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11711728.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / DNA Adducts; 884KT10YB7 / Ranitidine
  •  go-up   go-down


27. Bollen P, Bourgain C, Van Berlaer G, Duville L, Vandenplas Y: Non-Hodgkin lymphoma presenting as a solitary rectal polyp. J Pediatr Gastroenterol Nutr; 2000 Aug;31(2):193-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma presenting as a solitary rectal polyp.
  • [MeSH-major] Intestinal Polyps / pathology. Lymphoma, Non-Hodgkin / diagnosis. Rectum / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Colonoscopy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Gastrointestinal Hemorrhage. Humans. Hydrocortisone / administration & dosage. Immunophenotyping. Intestinal Mucosa / pathology. Leucovorin / administration & dosage. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10941976.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; WI4X0X7BPJ / Hydrocortisone; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate; COPADEM protocol
  •  go-up   go-down


28. Keller JJ, Offerhaus GJ, Hylind LM, Giardiello FM: Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev; 2002 Jul;11(7):670-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / prevention & control. Adenomatous Polyposis Coli / drug therapy. Colonic Neoplasms / drug therapy. Colonic Neoplasms / prevention & control. Sulindac / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Apoptosis / drug effects. Biopsy, Needle. Epithelium / drug effects. Epithelium / pathology. Female. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Middle Aged. Precancerous Conditions / pathology. Predictive Value of Tests. Rectum / drug effects. Rectum / pathology. Reference Values. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101116.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA53801
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac
  •  go-up   go-down






Advertisement